Man Group plc reduced its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 80.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,742 shares of the biotechnology company's stock after selling 79,629 shares during the period. Man Group plc's holdings in Aurinia Pharmaceuticals were worth $177,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Nuveen Asset Management LLC raised its holdings in shares of Aurinia Pharmaceuticals by 10.2% during the fourth quarter. Nuveen Asset Management LLC now owns 1,492,301 shares of the biotechnology company's stock valued at $13,401,000 after acquiring an additional 138,054 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Aurinia Pharmaceuticals by 49.9% in the fourth quarter. Millennium Management LLC now owns 87,421 shares of the biotechnology company's stock worth $785,000 after purchasing an additional 29,096 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Aurinia Pharmaceuticals by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 76,314 shares of the biotechnology company's stock valued at $685,000 after purchasing an additional 2,887 shares during the last quarter. Lazard Asset Management LLC boosted its holdings in Aurinia Pharmaceuticals by 341.9% during the 4th quarter. Lazard Asset Management LLC now owns 596,389 shares of the biotechnology company's stock valued at $5,355,000 after acquiring an additional 461,430 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at approximately $119,000. Hedge funds and other institutional investors own 36.83% of the company's stock.
Insider Activity at Aurinia Pharmaceuticals
In other news, insider Greg Keenan sold 8,305 shares of the business's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $8.23, for a total value of $68,350.15. Following the completion of the transaction, the insider now directly owns 153,484 shares in the company, valued at approximately $1,263,173.32. The trade was a 5.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Peter Greenleaf sold 195,593 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $1,564,744.00. Following the completion of the sale, the chief executive officer now owns 1,953,892 shares in the company, valued at $15,631,136. This trade represents a 9.10% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 343,898 shares of company stock valued at $2,753,094. Corporate insiders own 12.20% of the company's stock.
Wall Street Analyst Weigh In
Separately, Wall Street Zen upgraded shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, March 27th.
Read Our Latest Stock Report on Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Price Performance
AUPH stock traded down $0.13 during trading on Friday, reaching $7.86. 1,381,130 shares of the company were exchanged, compared to its average volume of 1,336,782. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The company has a market cap of $1.06 billion, a P/E ratio of -52.40 and a beta of 1.16. The stock's 50 day moving average price is $7.97 and its 200 day moving average price is $8.26. Aurinia Pharmaceuticals Inc. has a 52-week low of $5.15 and a 52-week high of $10.67.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.08 by $0.08. Aurinia Pharmaceuticals had a negative return on equity of 4.41% and a negative net margin of 10.23%. The business had revenue of $62.47 million for the quarter, compared to analysts' expectations of $61.06 million. As a group, analysts predict that Aurinia Pharmaceuticals Inc. will post 0.11 earnings per share for the current fiscal year.
Aurinia Pharmaceuticals Company Profile
(
Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Featured Stories
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
